Annovis Bio is a clinical-stage pharmaceutical company developing treatments for neurodegenerative diseases, primarily Alzheimer's disease and Parkinson's disease. The company's lead product, buntanetap, is an orally administered small molecule designed to simultaneously inhibit the synthesis of multiple neurotoxic proteins—amyloid-beta, tau, alpha-synuclein, and TDP43—that drive neurodegeneration, with the aim of improving cognitive and motor function. The company generates value through drug development partnerships, licensing, and plans to commercialize approved therapies through pharmaceutical partners who will target neurologists, geriatric specialists, and primary care physicians in markets representing millions of patients with significant unmet medical needs.